カリナン・セラピュ―ティクスに関するコメント

$カリナン・セラピュ―ティクス(CGEM.US)$
NEWS
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

Gainers:
• $カリナン・セラピュ―ティクス(CGEM.US)$ +22.4% (Cullinan Management and Taiho Pharmaceutical to collaborate to jointly develop and commercialize CLN081/TAS6417 and Taiho's acquisition of Cullinan Pearl)
• $Lordstown Motors(RIDE.US)$ +17.2% (closes asset purchase agreement with Foxconn)
• $アップラビン(APP.US)$ +15.5%(In reaction to earnings)
• $スマートレント(SMRT.US)$ +15.4%(In reaction to earnings)
• $クーパン(CPNG.US)$ +14.3%(In reaction to earn...

$カリナン・セラピュ―ティクス(CGEM.US)$ ISO this week in Biotech Pharma.